Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $31.8 million.

  • Allogene Therapeutics' Total Current Liabilities fell 226.58% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year decrease of 226.58%. This contributed to the annual value of $35.5 million for FY2024, which is 419.64% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Total Current Liabilities is $31.8 million, which was down 226.58% from $31.7 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Total Current Liabilities registered a high of $59.4 million during Q1 2023, and its lowest value of $30.0 million during Q1 2025.
  • In the last 5 years, Allogene Therapeutics' Total Current Liabilities had a median value of $37.5 million in 2023 and averaged $42.3 million.
  • Data for Allogene Therapeutics' Total Current Liabilities shows a peak YoY increase of 10452.31% (in 2021) and a maximum YoY decrease of 4920.8% (in 2021) over the last 5 years.
  • Allogene Therapeutics' Total Current Liabilities (Quarter) stood at $47.9 million in 2021, then grew by 12.15% to $53.7 million in 2022, then plummeted by 30.99% to $37.1 million in 2023, then decreased by 4.2% to $35.5 million in 2024, then fell by 10.39% to $31.8 million in 2025.
  • Its Total Current Liabilities was $31.8 million in Q3 2025, compared to $31.7 million in Q2 2025 and $30.0 million in Q1 2025.